NICE launch ambitious five-year patient access strategy
pharmafile | April 19, 2021 | News story | Sales and Marketing | NICE
NICE has unveiled its five-year plan to speed up patients’ access to the latest and most effective treatments with increased dynamism and collaboration at its centre.
In a statement today, NICE said that the COVID-19 pandemic has reaffirmed the need to place science and evidence at the heart of health and care decision making and improve outcomes for all patients across the healthcare system.
Through the 2021 – 2026 strategy NICE aims to be more proactive and engaged with the life science industry earlier in the innovation pathway, in order to allow patients to access new treatments faster.
In its announcement NICE stated they will have a new approach which will allow the organisation to evolve from producing full guidelines to adopting a more modular, living style of recommendations, allowing rapid updates that incorporate the latest evidence to reach healthcare professionals much faster.
The strategy has four key areas of focus: rapid technology evaluation, dynamic living guideline recommendations, increased guidance uptake, and leadership in scientific research.
Professor Gillian Leng CBE, NICE Chief Executive, said: “The new strategy sets out a vision for the future where NICE will be more dynamic, work more collaboratively, and continue to build on the excellent foundations of the last 22 years.
“Our work to produce rapid COVID-19 guidelines during the pandemic has hastened our desire for change. We demonstrated that we can be flexible and fleet of foot, without losing the rigour of our work, and we will now look to embed that approach in our day-to-day work.
“The world around us is changing. New treatments and technologies are emerging at a rapid pace, with real-world data driving a revolution in evidence. We will help busy healthcare professionals to navigate these new changes and ensure patients have access to the best care and latest treatments.”
NICE is holding an online launch event for the strategy today, in which details of the plan will be released and discussed by both NICE staff and healthcare professionals.
Kat Jenkins
Related Content
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Dual immunotherapy for bowel cancer now available under NHS
Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in …
